Physician profile
Edwin L Robey
NPI 1992783021
$863.19
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $44.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $374.47 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.00 | 2019 | |
| Astellas Pharma US INC | $57.61 | 2019 | |
| Dendreon Pharmaceuticals LLC | $50.11 | 2019 | |
| Travere Therapeutics, INC. | $50.09 | 2019 | |
| Photocure INC | $49.40 | 2019 | |
| Antares Pharma, INC. | $47.55 | 2019 | |
| Blue Earth Diagnostics | $38.29 | 2019 | |
| Acell, INC. | $37.48 | 2019 | |
| Abbott Laboratories | $17.94 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.66 | 2019 | |
| Olympus America INC. | $16.57 | 2019 | |
| Pfizer INC. | $14.66 | 2019 | |
| Neotract INC. | $14.00 | 2019 | |
| Endo Pharmaceuticals INC. | $13.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Robey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.